At the time of writing, Lyell Immunopharma Inc [LYEL] stock is trading at $13.47, up 68.59%. An important factor to consider is whether the stock is rising or falling in short-term value. The LYEL shares have gain 64.27% over the last week, with a monthly amount glided 55.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lyell Immunopharma Inc [NASDAQ: LYEL] stock has seen the most recent analyst activity on October 30, 2024, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $1 from $6. Previously, H.C. Wainwright downgraded its rating to Neutral on June 27, 2024, and dropped its price target to $1. On August 28, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $5 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $7 on November 14, 2022. Goldman downgraded its rating to a Neutral and reduced its price target to $7 on November 11, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on October 17, 2022, and assigned it a price target of $12. In a note dated July 12, 2021, Morgan Stanley initiated an Overweight rating and provided a target price of $25 on this stock.
For the past year, the stock price of Lyell Immunopharma Inc fluctuated between $7.65 and $53.90. Currently, Wall Street analysts expect the stock to reach $6.67 within the next 12 months. Lyell Immunopharma Inc [NASDAQ: LYEL] shares were valued at $13.47 at the most recent close of the market. An investor can expect a potential drop of -50.48% based on the average LYEL price forecast.
Analyzing the LYEL fundamentals
According to Lyell Immunopharma Inc [NASDAQ:LYEL], the company’s sales were 0.07M for trailing twelve months, which represents an 133.33% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -5546.88%, Pretax Profit Margin comes in at -5146.49%, and Net Profit Margin reading is -5146.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -0.74 and Total Capital is -0.93. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Lyell Immunopharma Inc [NASDAQ:LYEL] has a current ratio of 7.49. On the other hand, the Quick Ratio is 7.49, and the Cash Ratio is 2.91. Considering the valuation of this stock, the price to sales ratio is 2849.58, the price to book ratio is 0.59.
Transactions by insiders
Recent insider trading involved BRAWLEY OTIS W, Director, that happened on Mar 31 ’25 when 35640.0 shares were purchased. Director, Ramachandra Sumant completed a deal on Mar 21 ’25 to buy 0.2 million shares. Meanwhile, Director Klausner Richard bought 0.16 million shares on Mar 14 ’25.
